Virupaksha Organics Ltd. has emerged as a leader in the pharmaceutical industry, specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs). Founded in 2003, the company has built a reputation for innovation, quality, and sustainability. Under the dynamic leadership of Mr. Chandra Mouliswar Reddy Gangavaram, Virupaksha has grown its operations significantly, with state-of-the-art manufacturing facilities in Telangana, India.
The company’s facilities in Kazipally and Pashamylaram are certified by international and national regulatory bodies, including ISO 9001, ISO 14001, ISO 45001, ISO 50001, and GMP standards, ensuring that Virupaksha meets the highest levels of quality and safety in its production processes. These certifications highlight the company’s commitment to environmental sustainability, occupational safety, and best industry practices.
Virupaksha Organics is committed to excellence, innovation, and customer satisfaction, with a focus on developing sustainable solutions for the pharmaceutical industry. The company’s products are trusted by major pharmaceutical firms globally, as it continues to make strides towards becoming a research-driven organization. With a forward-thinking management team and a clear vision for the future, Virupaksha Organics is poised for rapid growth and continues to play a key role in advancing global healthcare.
As part of its corporate social responsibility (CSR), Virupaksha has initiated numerous welfare programs aimed at uplifting local communities and supporting environmental conservation, reinforcing its reputation as a responsible corporate citizen.
With continuous advancements and strategic partnerships, Virupaksha Organics Ltd. is well-positioned to expand its global footprint and contribute to the evolving pharmaceutical landscape.
Other Latest News
- <![CDATA[Rethinking Packaging: Materials, Risk, and Real-World Performance in Pharma Logistics ]]> Pharmaceutical Commerce As pharmaceutical supply chains continue to expand and operate under tighter timelines, the cold chain is becoming more complex, more distributed, and more exposed to variability than ever before. Temperature-sensitive medicines, including biologics, …
- <![CDATA[Pharma Pulse: A $7B Buyout, Tariff Refunds, Cold Chain Growth and More]]> Pharmaceutical Commerce Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast in which we bring you the latest insights shaping patient access, supply chain logistics, and healthcare innovation I’m your host, and let’s get into today’s headlines. Amid a growing demand for …
- Daiichi Sankyo shares slip after delaying annual earnings report BioSpace Daiichi Sankyo investors will have to wait two more weeks to hear the pharma’s earnings results for the 2025 fiscal year after the pharma on Friday announced a delay in its disclosure. Daiichi Sankyo’s 2025 fiscal year ended on March 31, and the company …
- <![CDATA[AbbVie Invests $1.4 Billion into New Manufacturing Campus in North Carolina ]]> Pharmaceutical Executive AbbVie announced a $1.4 billion investment to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina. Emerging Pharma Leaders nominations are now open! Do you know someone who can make tough decisions that continue to face …
- <![CDATA[FDA Expands Approval for Dupixent for Young Children with Uncontrolled Chronic Spontaneous Urticaria ]]> Pharmaceutical Executive FDA expanded its approval of Dupixent (dupilumab) to include children aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite treatment with histamine-1 antihistamines. Emerging Pharma Leaders nominations are now open! Do …
- <![CDATA[The Long Wait for Rare Disease Treatment Approval: Q&A with Dr. Patricia E. Greenstein]]> Pharmaceutical Executive Earlier this year, FDA issued draft guidance that allows for a wider range of data to be used in clinical trials. This includes the incorporation of real-world data (RWD) with study data. For patients with rare diseases, this shift may help solve a serious …
- Medicus Pharma advances Skinject in rare disease – ICYMI Proactive USA Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress in advancing its Skinject program, highlighting a newly submitted orphan drug designation application with the US Food and Drug Administration targeting Gorlin syndrome, a rare genetic …
- <![CDATA[FDA Issues CRL to AbbVie for TrenibotulinumtoxinE’s Biologics License Application ]]> Pharmaceutical Executive AbbVie received a Complete Response Letter (CRL) from the FDA for its Biologics License Application (BLA) for trenibotulinumtoxinE. Emerging Pharma Leaders nominations are now open! Do you know someone who can make tough decisions that continue to face …
- Revolutionizing Pharmaceutical Manufacturing with Data Analytics Pharma Tech Outlook By Pharma Tech Outlook | Friday, April 24, 2026 Fremont, CA: Data analytics has emerged as a critical asset in the pharmaceutical industry, boosting productivity and supporting success across all stages of the production process. By leveraging data, …
- Sustainable Pharma Through a Reimagined PVP Supply Chain Pharma Tech Outlook The pharmaceutical industry is undergoing a major transformation, with sustainability emerging as a central principle reshaping every aspect of drug development and manufacturing. A critical focus lies in the supply chain for excipients—the inactive …
- J.P. Morgan upgrades Taiwan, tech to overweight; cuts India to neutral amid AI surge and stagflation The Hindu Business Line J.P. Morgan has raised its Asia equity strategy allocation for Taiwan and the broader technology sector to overweight, while downgrading Indian equities to neutral, citing an accelerating AI investment cycle and a stagflationary macro backdrop as the twin …
- CDC Declines to Publish Study Questioning COVID-19 Vaccine Effectiveness Natural News Introduction The Centers for Disease Control and Prevention (CDC) will not publish a study on the effectiveness of COVID-19 vaccination, its top official confirmed late on April 22, 2026. Dr. Jay Bhattacharya, who is serving as acting CDC director, said …
- Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics BioPharma Dive Today, a brief rundown of news from Eli Lilly and the Food and Drug Administration, as well as updates from Regeneron, Amgen, BridgeBio Oncology Therapeutics and Novo Nordisk that you may have missed. Eli Lilly shares sagged Friday after the latest weekly …
- India faces 'bad or ugly' macro outcomes from West Asia crisis, says Sanjeev Prasad; but Nifty earnings may hold up The Economic Times India's equity markets are caught in a cycle of reacting to daily news from West Asia with no clear direction in sight — and the macroeconomic consequences of the ongoing conflict are being underestimated, according to Sanjeev Prasad, Co-Head, at Kotak …
- Cardiometabolic trials: Using expertise to turn complexity into robust results Pharmaceutical Technology For sponsors running cardiometabolic programs, early clinical development often hinges on one question: can a site deliver predictable recruitment, high participant retention, and clean, decision-grade data—on time and to protocol? Yet many trial teams …
- Business News | Hindusthan National Glass Official Says Glass Industry Survived Energy Shock, but Costs and Gas Supply Remain Concern Latestly New Delhi [India], April 24 (ANI): The ongoing West Asia conflict has sent ripples through India's glass manufacturing sector, with Hindusthan National Glass (HNG) Chief Strategy Officer Suraj Mehta saying the industry faced a severe energy crunch due …
- How Dave Ricks keeps Lilly looking beyond its hit weight loss drugs Semafor Dave Ricks does not know how many of his fellow CEOs are on Mounjaro and Zepbound, but the answer is “not zero,” Lilly’s CEO said at Semafor World Economy last week. The popularity of the two GLP-1 treatments has made the Indianapolis-based drugmaker one …
- The Hidden Cost of Licensing in Biologic Drug Development World Pharma Today The Hidden Cost of Licensing in Biologic Drug Development – and Why More Biotech Startups are Rethinking it Key Takeaways: Platform licensing costs in biopharma are often underestimated in early financial modelling Royalty stacks can compound across …
- ‘ICE Out’ legislation passes; School closure vote delayed; Renter protection lawsuit | Morning Roundup Billy Penn - Pennsylvania #BILLYPENNGRAM OF THE DAY Carrying a tune (Photo by @denisewalksphilly) The package of seven bills restricting federal immigration enforcement activities in Philadelphia will now go to Mayor Cherelle Parker’s desk, backed by a veto-proof majority. “This …
- Utah joins multimillion dollar opioid settlement against Albertsons KOAL - Utah By Wyatt Boyle | KOAL News Collecting their dues for the devastating opioid crisis, the state of Utah has joined a multistate agreement requiring Albertsons to pay $773.7 million in reparations. Utah is projected to receive at least $10.7 million from the …
- Pharma Friday – April 24, 2026 Endocrine News An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Sanofi’s Tzield Approved in the US to Delay Onset of Stage 3 Type 1 Diabetes in Young Children The U.S. Food and Drug Administration (FDA) has approved …
- Cyclist, 30, dies after horror crash led to 'knee complications' as tributes pour in Daily Star Cristian Camilo Munoz, 30, has died(Image: Getty Images) A 30-year-old professional cyclist has tragically died after a horror crash that led to knee complications at the Tour du Jura. Cristian Camilo Munoz was racing for Colombian team Nu Colombia at the …
- Vistin Reports First Quarter 2026 Results RTTNews Vistin Pharma ASA (VISTN), a pharmaceutical manufacturing company, announced on Friday financial results for the first quarter of 2026. Vistin produces an estimated 10% of the world's metformin hydrochloride, an essential medication in the treatment …
- Trump’s prescription drug math makes no sense. RFK Jr. and Dr. Oz have defended it anyway KIFI Local News 8 - Idaho By Daniel Dale, CNN (CNN) — President Donald Trump’s claims about prescription drug prices make no mathematical sense. But his team – including Health Secretary Robert F. Kennedy Jr. this week – keeps straining to defend them. Since last year, Trump has …
- Biomednewsbreaks Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Adds Robert Langer, Stephen Brannan To Scientific Advisory Board MENAFN (MENAFN- Investor Brand Network) This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced the appointments of Dr. Robert Langer and Dr. Stephen Brannan to its …
- Catching Our Eye News Roundup, April 24, 2026 Ohio Capital Journal Every morning in the Ohio Capital Journal’s free newsletter, The Eye-Opener, we round up the news and commentary from across Ohio and around the country and world that is catching our attention. We call this feature Catching Our Eye, republished here. …
- April is Parkinson's Awareness Month, continued Village News - California Irene Miller / Fallbrook Parkinson Support Group MJFox Research News on March 11, 2026, reported on Stem Cell Therapy for Parkinson’s given approval in Japan. A dopamine neuron replacement therapy developed by Sumitomo Pharma known as raguneprocel, a …
- After waiting years for justice, many Purdue opioid victims are defeated — by paperwork Yahoo News By Dietrich Knauth April 24 (Reuters) - Tammy Blanton’s life unraveled after years of taking opioids initially prescribed for migraines, according to her daughter Mary Anne, who says the drugs left her mother isolated, unemployed and estranged from her …
- Stock Market: Sensex, Nifty plunge on high oil prices, massive selling in IT stocks News9 Live Stock Market on 24 April 2026: Sensex and Nifty updates (Pic: TV9) Mumbai: The BSE Sensex declined dropped 999.79 points to settle at 76,664.21 on Friday. The NSE Nifty went down slumped 275.10 points to finish at 23,897.95. The benchmark indices plummeted …
- Plans approved for $1bn mental health hospital and college in Oxford World Construction Network Eric Parry Architects has announced the approval of a £750m ($1bn) development at Warneford Park in Oxford, UK, which will establish a new mental health hospital and medical research centre alongside the conversion of listed buildings into a postgraduate …
- Executive Order Sparks New Phase for Psychedelic Biotech, Risks Remain Investing News Network On April 18, President Trump was joined by top health officials in the Oval Office to sign Accelerating Medical Treatments For Serious Mental Illness, an executive order to expand research into ibogaine. This signals the strongest federal endorsement yet …
- Greek court awards 300,000 Euros for death after AstraZeneca Covid vaccination Europe Reloaded The Greek government must pay €300,000 to the family of a woman who died after her AstraZeneca Covid vaccination in a landmark court decision acknowledging the unfairness of coercing citizens into entering a death lottery for the purported public good. …
- FTSE 100 Live: Stocks retreat as oil remains elevated, Iran in... Proactive UK FTSE 100 falls 78 points to 10,379 BoE policymaker says markets aren't reflecting reality Mondi declines 8% on Q1 report Brent crude holds above $100 UK retail sales rise 0.7% in March 4.52pm: Losing day London stocks finished the week on a sour note …
- Non-animal testing goes mainstream, but success hinges on smart use Clinical Trials Arena As new approach methodologies (NAMs) burst onto the scene amid the wider shift away from animal testing, biotech and pharma companies are increasingly harnessing these models to better guide drug development. In a keynote session at the 2026 AngloNordic …
- International childhood vaccine campaign grows STAT - Massachusetts Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. It’s my birthday tomorrow. What’s your favorite off-the-wall rendition of a birthday anthem? I love this version from Black Country, New Road …
- Lilly’s CAR-T devotion; CBER’s next top dog? PharmaVoice Some of the biggest news and trends captured in PharmaVoice’s newsletter this week. Sign up here to receive the newsletter daily. Lilly’s latest CAR-T buyout A push by Eli Lilly to acquire genetic platforms like the multibillion-dollar acquisition of in …
- After waiting years for justice, many Purdue opioid victims are defeated - by paperwork WKZO - Michigan By Dietrich Knauth April 24 (Reuters) – Tammy Blanton’s life unraveled after years of taking opioids initially prescribed for migraines, according to her daughter Mary Anne, who says the drugs left her mother isolated, unemployed and estranged from her …
- Radiopharmaceuticals Market Size to Exceed USD 15.21 Billion By 2035 Rising Cancer Cases Boost the Market Demand Business Upturn According to Precedence Research, the global radiopharmaceuticals market size is estimated to reach nearly USD 15.21 billion by 2035, increasing from USD 8.28 billion in 2026, growing at a strong CAGR of 7.31% from 2026 to 2035. Ottawa, April 24, 2026 ( …
- GOP faces Planned Parenthood funding dilemma Politico Driving the Day FUNDING DISCORD — Anti-abortion activists and some GOP lawmakers warn that the push from Republican leadership for a narrow party-line bill could trigger the return of hundreds of millions in Medicaid funding to Planned Parenthood, POLITICO …
- What is the Organon deal, and why are Sun Pharma's shares falling? Business Today Shares of Sun Pharma fell over 3% on Friday after reports of a potential acquisition of US-based Organon & Co surfaced, with analysts raising concerns over valuation and execution risks linked to the deal. The stock declined 3.61% to hit a low of ₹1, …
- BT Closing Bell | Sensex, Nifty snap two-week winning streak; IT stocks lead losers today Business Today Domestic equity benchmarks BSE Sensex and NSE Nifty snapped their two-week winning run, declining for the third consecutive session on Friday, dragged by selling pressure in IT heavyweights amid rising crude oil prices and uncertainty over the US-Iran …
- Big business shows up in final days of arguments at Supreme Court KTVZ - Oregon (CNN) — Big businesses are lining up at the Supreme Court as the justices hear the final arguments of the term, pressing the conservative majority to shield industries from multimillion-dollar jury verdicts, limit the marketing of generic drugs and neuter …
- Radiopharmaceuticals Market Size to Exceed USD 15.21 Billion By 2035 Rising Cancer Cases Boost the Market Demand EIN Presswire Ottawa, April 24, 2026 (GLOBE NEWSWIRE) -- Rising global incidence of cancer and cardiovascular diseases is driving demand for advanced diagnostic imaging and targeted radiopharmaceutical therapies. What is the Radiopharmaceuticals Market Size in 2026? The …
- Sun Pharma looks to outshine rival bids with $13 billion Organon offer ETPharma.com Mumbai: Dilip Shanghvi is going ahead with his biggest bet ever, by submitting a binding offer of $13 billion to acquire US-based Organon & Co, said people in the know, as part of an ambitious bid to transform Indian generics champion Sun …
- When the Game Ends, DeMaurice Smith Fights for the Players WHYY FM - Pennsylvania DAVID GREENE, HOST: Welcome to Sports in America, everybody. And I want to talk this week about a moment that a lot of NFL players still remember. It is the moment when they are drafted, when they get on the phone with a coach of one of the teams in the …
- Regeneron cuts White House pricing deal, offers new gene therapy for free Pharmaceutical Technology It’s been a busy few days for Regeneron Pharmaceuticals, which has inked a drug pricing agreement with the White House, while pledging to offer its newly approved rare hearing loss gene therapy, Otarmeni (lunsotogene parvec-cwha), for free to American …
- The best inventory management software of 2026: Expert tested and reviewed ZDNet If you're still managing inventory in spreadsheets (or worse, on paper), you already know how quickly things fall apart. One stockout during a busy sales week can cost you thousands. A single miscounted stock keeping unit, or SKU, can snowball into a …
- Ainewsbreaks Silo Pharma Inc. (NASDAQ: SILO) Expands Into AI With Qwikagents Asset Acquisition MENAFN (MENAFN- Investor Brand Network) Silo Pharma (NASDAQ: SILO) announced a strategic expansion into artificial intelligence as a second line of business following its acquisition of assets from Qwikagents, a platform designed to deploy autonomous AI agents …
- Local health facility leaders defend 340B program amid concerns of potential fraud, fund usage Wadena Pioneer Journal - Minnesota WADENA — As Minnesota lawmakers revisit protections tied to the federal 340B drug discount program, hospital leaders say the stakes are high for critical access hospitals that rely on the federal drug pricing program to help offset rising costs of health …
- Sensex, Nifty Trade Lower In Early Deals, IT And Pharma Stocks Under Pressure MENAFN (MENAFN- IANS) Mumbai, April 24 (IANS) The domestic equity markets saw negative performance in early hours on Friday amid elevated geopolitical tensions and the Q4 earnings season.Sensex was trading at 77,263, down 0.51 per cent or 400 points, while Nifty …